155 related articles for article (PubMed ID: 30355990)
1. Synthesis of Novel FTY720 Analogs with Anticancer Activity through PP2A Activation.
Shrestha J; Ki SH; Shin SM; Kim SW; Lee JY; Jun HS; Lee T; Kim S; Baek DJ; Park EY
Molecules; 2018 Oct; 23(11):. PubMed ID: 30355990
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Biological Evaluation of FTY720 (Fingolimod) Derivatives with Aromatic Head Group as Anticancer Agents.
Lee T; Moon HS; Kim SW; Shrestha J; Shin SM; Lee JY; Kim S; Park EY; Baek DJ
Chem Pharm Bull (Tokyo); 2018; 66(10):1015-1018. PubMed ID: 30270236
[TBL] [Abstract][Full Text] [Related]
3. Development of novel PP2A activators for use in the treatment of acute myeloid leukaemia.
Toop HD; Dun MD; Ross BK; Flanagan HM; Verrills NM; Morris JC
Org Biomol Chem; 2016 May; 14(20):4605-16. PubMed ID: 27102578
[TBL] [Abstract][Full Text] [Related]
4. Disruption and inactivation of the PP2A complex promotes the proliferation and angiogenesis of hemangioma endothelial cells through activating AKT and ERK.
Xie F; Bao X; Yu J; Chen W; Wang L; Zhang Z; Xu Q
Oncotarget; 2015 Sep; 6(28):25660-76. PubMed ID: 26308070
[TBL] [Abstract][Full Text] [Related]
5. Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
Smith AM; Dun MD; Lee EM; Harrison C; Kahl R; Flanagan H; Panicker N; Mashkani B; Don AS; Morris J; Toop H; Lock RB; Powell JA; Thomas D; Guthridge MA; Moore A; Ashman LK; Skelding KA; Enjeti A; Verrills NM
Oncotarget; 2016 Jul; 7(30):47465-47478. PubMed ID: 27329844
[TBL] [Abstract][Full Text] [Related]
6. Fingolimod targeting protein phosphatase 2A differently affects IL-33 induced IL-2 and IFN-γ production in CD8(+) lymphocytes.
Ottenlinger F; Schwiebs A; Pfarr K; Wagner A; Grüner S; Mayer CA; Pfeilschifter JM; Radeke HH
Eur J Immunol; 2016 Apr; 46(4):941-51. PubMed ID: 26683421
[TBL] [Abstract][Full Text] [Related]
7. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
[TBL] [Abstract][Full Text] [Related]
8. PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential.
Velmurugan BK; Lee CH; Chiang SL; Hua CH; Chen MC; Lin SH; Yeh KT; Ko YC
J Cell Physiol; 2018 Feb; 233(2):1300-1311. PubMed ID: 28516459
[TBL] [Abstract][Full Text] [Related]
9. Novel effects of FTY720 on perinuclear reorganization of keratin network induced by sphingosylphosphorylcholine: Involvement of protein phosphatase 2A and G-protein-coupled receptor-12.
Park MK; Park S; Kim HJ; Kim EJ; Kim SY; Kang GJ; Byun HJ; Kim SH; Lee H; Lee CH
Eur J Pharmacol; 2016 Mar; 775():86-95. PubMed ID: 26872988
[TBL] [Abstract][Full Text] [Related]
10. Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.
Cristóbal I; González-Alonso P; Daoud L; Solano E; Torrejón B; Manso R; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Mar Drugs; 2015 May; 13(6):3276-86. PubMed ID: 26023836
[TBL] [Abstract][Full Text] [Related]
11. In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
Garsi JB; Sernissi L; Vece V; Hanessian S; McCracken AN; Simitian G; Edinger AL
Eur J Med Chem; 2018 Nov; 159():217-242. PubMed ID: 30292898
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of PP2A-Activating PF-543 Derivatives and Investigation of Their Inhibitory Effects on Pancreatic Cancer Cells.
Kim SB; Oh YS; Kim KJ; Cho SW; Park SK; Baek DJ; Park EY
Molecules; 2022 May; 27(10):. PubMed ID: 35630821
[TBL] [Abstract][Full Text] [Related]
13. FTY720-induced enhancement of autophagy protects cells from FTY720 cytotoxicity in colorectal cancer.
Li J; Wang SW; Zhang DS; Sun Y; Zhu CY; Fei Q; Hu J; Zhang C; Sun YM
Oncol Rep; 2016 May; 35(5):2833-42. PubMed ID: 26985637
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
15. Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.
Shouse G; de Necochea-Campion R; Mirshahidi S; Liu X; Chen CS
Oncotarget; 2016 Sep; 7(38):61081-61092. PubMed ID: 27531894
[TBL] [Abstract][Full Text] [Related]
16. The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction.
De Palma RM; Parnham SR; Li Y; Oaks JJ; Peterson YK; Szulc ZM; Roth BM; Xing Y; Ogretmen B
FASEB J; 2019 Jun; 33(6):7647-7666. PubMed ID: 30917007
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effects of vemurafenib and fingolimod (FTY720) in vemurafenib‑resistant melanoma cell lines.
Takahashi T; Abe N; Kanoh H; Banno Y; Seishima M
Mol Med Rep; 2018 Dec; 18(6):5151-5158. PubMed ID: 30320355
[TBL] [Abstract][Full Text] [Related]
18. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
[TBL] [Abstract][Full Text] [Related]
19. Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review.
Cristóbal I; Madoz-Gúrpide J; Manso R; González-Alonso P; Rojo F; García-Foncillas J
Curr Med Res Opin; 2016 Jun; 32(6):1137-41. PubMed ID: 26950691
[TBL] [Abstract][Full Text] [Related]
20. FTY720 inhibited proinflammatory cytokine release and osteoclastogenesis induced by Aggregatibacter actinomycetemcomitans.
Yu H; Herbert BA; Valerio M; Yarborough L; Hsu LC; Argraves KM
Lipids Health Dis; 2015 Jul; 14():66. PubMed ID: 26138336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
